Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for
hematologic malignancies and immunodeficiencies, though it poses many risks to the …

Introduction: Lung chronic graft-versus-host disease (GVHD) is a rare and life-threatening
disorder, with an incidence of 3-10% in allogenic hematopoietic stem cell transplantation …

DISCUSSION: Pulmonary GVHD is a rare complication after BMT. GVHD is classified into
acute and chronic, with acute GVHD typically occurring within 100 days of transplant …

'Much of what medical researchers conclude in their studies is misleading, exaggerated, or
flat-out wrong.'That was the headline in an article titled 'Lies, Damned Lies and Medical …

Background The primary pulmonary manifestation of chronic graft vs host disease (GvHD) is
the development of bronchiolitis obliterans. Other pulmonary manifestations of chronic …

This consensus statement established under the auspices of the German working group on
BM and blood stem cell transplantation (DAG-KBT), the German Society of Hematology and …

History An 18-year-old man was diagnosed with precursor B-cell lymphoblastic leukemia
and underwent transplantation of hematopoietic stem cells from his human leukocyte …

Chronic graft-versus-host disease (cGvHD) is a common complication after allogeneic
haematopoietic stem cell transplantation, characterised by a broad disease spectrum that …

A 19-year-old woman with extensive, persistent chronic graft versus host disease (GVHD),
following an HLA-identical bone marrow graft for acute leukemia, developed rapidly …

Bronchiolitis obliterans syndrome (BOS) after allogeneic HSCT is the only formally
recognized manifestation of lung chronic graft-versus-host disease (GVHD). Other lung …